Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first in human study of cannabis-based therapies for the treatment of early to moderate Parkinson's disease ("PD").

Next Previous
Trial Profile

A first in human study of cannabis-based therapies for the treatment of early to moderate Parkinson's disease ("PD").

Status: Planning
Phase of Trial: Phase 0

Latest Information Update: 30 Dec 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabinoid therapeutics GB Sciences (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; First in man
  • Sponsors GB Sciences

Most Recent Events

  • 20 Dec 2019 According to a GB Sciences media release, the company is planning to initiate this study in early 2020.
  • 12 Apr 2018 New trial record
  • 10 Apr 2018 According to a GB Sciences media release, company is planning to file an Exploratory IND application to the US FDA. This study is expected to start in early 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top